"As a Duke Health hospital, Duke Raleigh Hospital offers exceptional medical care and an outstanding experience that focuses on meeting your needs. Our mission is to improve health, advance knowledge, and inspire hope. Our vision is to be the trusted leader in healthcare through outstanding quality, an unparalleled patient experience, innovative care delivery, and our commitment to the community."

During the past decade, Duke Raleigh Hospital conducted 47 clinical trials. In the 10-year time frame, 47 clinical trials started and 36 clinical trials were completed, i.e. on average, 76.6% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 22 clinical trials were completed. i.e. 122.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Duke Raleigh Hospital" #1 sponsor was "National Cancer Institute (NCI)" with 23 trials, followed by "Duke University" with 13 trials sponsored, "SWOG Cancer Research Network" with 13 trials sponsored, "Alliance for Clinical Trials in Oncology" with 9 trials sponsored and "Gynecologic Oncology Group" with 9 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Duke Raleigh Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 32 trials as a collaborator, "NRG Oncology" with 9 trials as a collaborator, "Canadian Cancer Trials Group" with 3 trials as a collaborator, "Cancer and Leukemia Group B" with 2 trials as a collaborator and "Duke University" with 2 trials as a collaborator. Other collaborators include 21 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Duke Raleigh Hospital" are "Recurrent Squamous Cell Lung Carcinoma" (7 trials), "Ovarian Seromucinous Carcinoma" (6 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (6 trials), "Recurrent Ovarian Carcinoma" (5 trials) and "Breast Cancer" (4 trials). Many other conditions were trialed in "Duke Raleigh Hospital" in a lesser frequency.

Most popular intervention types in "Duke Raleigh Hospital" are "Drug" (56 trials), "Other" (49 trials), "Biological" (21 trials), "Procedure" (10 trials) and "Radiation" (10 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (24 trials), "Quality-of-Life Assessment" (19 trials), "Paclitaxel" (14 trials), "Questionnaire Administration" (11 trials) and "Carboplatin" (10 trials). Other intervention names were less common.

The vast majority of trials in "Duke Raleigh Hospital" are 51 trials for "All" genders, 20 trials for "Female" genders and 8 trials for "Male" genders.

Currently, there are NaN active trials in "Duke Raleigh Hospital". undefined are not yet recruiting, 13 are recruiting, 28 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 26 completed trials in Duke Raleigh Hospital, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Duke Raleigh Hospital, 2 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 44 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 12 trials that are defined as “Not Applicable".